Abstract
This study evaluated and compares the antioxidant activity of six resveratrol analogues. The analogues 4’- Hydroxyphenyl-benzo[d]thiazole (A), p-(N,N-dimethyl)aminobenzylidene-2-aminothiophenol (B) and p-Nitrobenzylidene- 2-aminothiophenol (C) were synthesized and the antioxidant activity was evaluated using the DPPH method. A descriptive statistical analysis and ANOVA followed by the Tukey test, with the aid of software. The best antioxidant activity was demonstrated by compound C (half maximal inhibitory concentration (IC50) = 18.45µM), this compound is two times more active than resveratrol (IC50= 37.28µM). Taken together, the data presented herein suggest that these molecules might serve as potential antioxidant considering that molecular modification is an effective strategy. As such, the compounds described herein can serve as prototypes for further research and the development of novel antioxidant agents.
Keywords: Antioxidants, Chemical synthesis, Resveratrol, Statistical analysis, Structure-activity relationship, Thio-Schiff bases.
Letters in Drug Design & Discovery
Title:Antioxidant Activity of Thio-Schiff Bases
Volume: 10 Issue: 7
Author(s): Juliana Alves dos Santos, Rebeca Mol Lima, Thamiris Vilela Pereira, Antonio Marcio Resende do Carmo, Nadia Rezende Barbosa Raposo and Adilson David da Silva
Affiliation:
Keywords: Antioxidants, Chemical synthesis, Resveratrol, Statistical analysis, Structure-activity relationship, Thio-Schiff bases.
Abstract: This study evaluated and compares the antioxidant activity of six resveratrol analogues. The analogues 4’- Hydroxyphenyl-benzo[d]thiazole (A), p-(N,N-dimethyl)aminobenzylidene-2-aminothiophenol (B) and p-Nitrobenzylidene- 2-aminothiophenol (C) were synthesized and the antioxidant activity was evaluated using the DPPH method. A descriptive statistical analysis and ANOVA followed by the Tukey test, with the aid of software. The best antioxidant activity was demonstrated by compound C (half maximal inhibitory concentration (IC50) = 18.45µM), this compound is two times more active than resveratrol (IC50= 37.28µM). Taken together, the data presented herein suggest that these molecules might serve as potential antioxidant considering that molecular modification is an effective strategy. As such, the compounds described herein can serve as prototypes for further research and the development of novel antioxidant agents.
Export Options
About this article
Cite this article as:
Santos Alves dos Juliana, Lima Mol Rebeca, Pereira Vilela Thamiris, Carmo Marcio Resende do Antonio, Raposo Rezende Barbosa Nadia and Silva David da Adilson, Antioxidant Activity of Thio-Schiff Bases, Letters in Drug Design & Discovery 2013; 10 (7) . https://dx.doi.org/10.2174/1570180811310070002
DOI https://dx.doi.org/10.2174/1570180811310070002 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Minireview: Peptide Analogs and Short Sequence Oligopeptides as Modulators of Skin Pigmentation
Current Topics in Medicinal Chemistry Marinobufagenin in Urine: A Potential Marker of Predisposition to Ethanol and a Target for Spironolactone
Current Hypertension Reviews Machine Learning and Molecular Dynamics Based Insights into Mode of Actions of Insulin Degrading Enzyme Modulators
Combinatorial Chemistry & High Throughput Screening AdipoRon: A Novel Insulin Sensitizer in Various Complications and the Underlying Mechanisms: A Review
Current Molecular Pharmacology Cyclopeptide Analogs for Generating New Molecular and 3D Diversity
Combinatorial Chemistry & High Throughput Screening Neural Receptors Associated with Depression: A Systematic Review of the Past 10 Years
CNS & Neurological Disorders - Drug Targets Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma on Cirrhosis: State of the Art and Future Perspectives
Recent Patents on Anti-Cancer Drug Discovery Immunotherapy for Malignant Melanoma Robert
Current Stem Cell Research & Therapy Release of α-Glutathione s-Transferase (α-GST) and Hepatocellular Damage Induced by Helicobacter pylori and Eradication Treatment
Current Drug Safety Safety of Vascular Endothelial and Hepatocyte Growth Factor Gene Therapy in Patients with Critical Limb Ischemia
Current Neurovascular Research Leukocyte Function-Associated Antigen-1: Structure, Function and Application Prospects
Protein & Peptide Letters Treatment of Alzheimer's Disease: Classical Therapeutic Approach
Current Pharmaceutical Analysis Minocycline as Add-On Treatment Decreases the Negative Symptoms of Schizophrenia; A Randomized Placebo-Controlled Clinical Trial
Recent Patents on Inflammation & Allergy Drug Discovery Brain Structural Effects of Psychopharmacological Treatment in Bipolar Disorder
Current Neuropharmacology Preface (Walter H. Kaye)
Current Drug Targets - CNS & Neurological Disorders Nanotechnology can Provide Therapeutic Agent by Targeting Molecular Structures of SARS-CoV-2 (COVID-19): A Mini-Review
Letters in Drug Design & Discovery The Effect of Vitamin D3 Supplementation on Serum BDNF, Dopamine, and Serotonin in Children with Attention-Deficit/Hyperactivity Disorder
CNS & Neurological Disorders - Drug Targets In Silico Repurposing of J147 for Neonatal Encephalopathy Treatment: Exploring Molecular Mechanisms of Mutant Mitochondrial ATP Synthase
Current Pharmaceutical Biotechnology Genotyping OLR1 Gene: A Genomic Biomarker for Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Pandemic of Atopic Diseases - A Lack of Microbial Exposure in Early Infancy?
Current Drug Targets - Infectious Disorders